Zivo Bioscience (ZIVO) Price & Analysis

Compare

39 Followers

ZIVO Stock Chart & Stats

$7.54

-$0.17(-0.89%)

At close: Jan 08 4:00 PM EST

$7.54

-$0.17(-0.89%)

Day’s Range― - ―

52-Week Range$6.95 - $22.00

Previous CloseN/A

Volume326.00

Average Volume (3M)586.00

Market Cap

$34.96M

Enterprise Value$61.41M

Total Cash (Recent Filing)$57.22K

Total Debt (Recent Filing)$432.30K

Price to Earnings (P/E)―

Beta1.40

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.35

Shares Outstanding3,888,595

10 Day Avg. Volume232

30 Day Avg. Volume586

Financial Highlights & Ratios

PEG Ratio0.37

Price to Book (P/B)-142.41

Price to Sales (P/S)466.38

P/FCF Ratio-17.00

Enterprise Value/Market Cap1.76

Enterprise Value/Revenue293.80

Enterprise Value/Gross Profit927.53

Enterprise Value/Ebitda-7.26

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Licensing AgreementsZIVO is engaged in constructive discussions with two major global animal health companies regarding potential licensing agreements for ZIVO’s coccidiosis product.

Poultry Health OpportunitiesPositive results from the avian flu study and plans for an additional trial are viewed favorably as it could expand ZIVO’s opportunities in poultry health.

Bears Say

Balance Sheet ConcernsThere is a risk that a deal does not come to fruition, combined with lingering concerns regarding the balance sheet and access to capital.

Capital Raising ChallengesOngoing challenges of raising capital as an unlisted security is a concern.

Cash And Debt SituationZIVO had cash and equivalents of $159K and debt of $355K, and it is expected to burn an average of $1.7M per quarter through 2025, relying on private placements or high interest-rate loans for funding.

Zivo Bioscience News

Zivo Bioscience CFO Resigns, Interim Successor Appointed

Zivo Bioscience ( ($ZIVO) ) has provided an update. On December 19, 2025, Zivo Bioscience’s Chief Financial Officer,...

23d ago

ZIVO

Zivo Bioscience Board Member Nola Masterson Resigns

An announcement from Zivo Bioscience ( ($ZIVO) ) is now available. On August 12, 2025, Nola Masterson resigned...

5M ago

ZIVO

Zivo Bioscience Issues Convertible Debt Offering

The latest update is out from Zivo Bioscience ( ($ZIVO) ). On July 8, 2025, Zivo Bioscience, Inc....

6M ago

ZIVO

Zivo Bioscience Announces Board Election and Approvals

An announcement from Zivo Bioscience ( ($ZIVO) ) is now available. At the annual meeting of shareholders held...

7M ago

ZIVO

Zivo Bioscience Strengthens Board with New Director Appointment

Zivo Bioscience (ZIVO) has provided an announcement. ZIVO Bioscience Inc. has expanded its Board of Directors and welcomed...

1y ago

ZIVO

Zivo and animal health firm launch study targeting coccidiosis treatment

ZIVO Bioscience announces the initiation of a 42-day confirmatory study targeting coccidiosis in collaboration with a major global...

2y ago

ZIVO

Zivo Bioscience Enhances Equity Incentive Plans for Leadership

Zivo Bioscience (ZIVO) just unveiled an announcement. Zivo Bioscience, Inc. has implemented new incentive plans to motivate non-employee...

2y ago

ZIVO

Zivo Bioscience downgraded to Hold from Buy at Maxim (yesterday)

Maxim yesterday morning downgraded Zivo Bioscience to Hold from Buy without a price target. The firm is positive...

2y ago

ZIVO

Zivo Bioscience downgraded to Hold from Buy at Maxim

Maxim downgraded Zivo Bioscience to Hold from Buy. Published first on TheFly – the ultimate source for real-time,...

2y ago

ZIVO

Zivo Bioscience Inc Faces Nasdaq Delisting and Shifts to OTC Markets

Zivo Bioscience Inc (ZIVO) has released an update. Nasdaq is set to delist Zivo Bioscience, Inc.’s common stock...

2y ago

ZIVO

Zivo starts efficacy study of immune modulating to treat coccidiosis in chickens

Zivo Bioscience announces the initiation of a 42-day study to further validate the efficacy of its novel immune-modulating...

2y ago

ZIVO

Zivo Bioscience files to sell common stock, no amount given

17:11 EDT Zivo Bioscience files to sell common stock, no amount given Published first on TheFly – the...

2y ago

ZIVO

Zivo Bioscience reports ‘positive’ results from month-long coccidiosis trial

Zivo Bioscience announced positive results from a month-long coccidiosis trial in broiler chickens that was conducted by an...

2y ago

ZIVO

Zivo Bioscience files to sell 2.99M shares of common stock for holders

06:06 EDT Zivo Bioscience files to sell 2.99M shares of common stock for holders Published first on TheFly...

2y ago

ZIVO

ZIVO FAQ

What was Zivo Bioscience Inc’s price range in the past 12 months?

Zivo Bioscience Inc lowest stock price was $6.95 and its highest was $22.00 in the past 12 months.

What is Zivo Bioscience Inc’s market cap?

Zivo Bioscience Inc’s market cap is $34.96M.

When is Zivo Bioscience Inc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Zivo Bioscience Inc’s earnings last quarter?

Currently, no data Available

Is Zivo Bioscience Inc overvalued?

According to Wall Street analysts Zivo Bioscience Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Zivo Bioscience Inc pay dividends?

Zivo Bioscience Inc does not currently pay dividends.

What is Zivo Bioscience Inc’s EPS estimate?

Zivo Bioscience Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Zivo Bioscience Inc have?

Zivo Bioscience Inc has 3,888,595 shares outstanding.

What happened to Zivo Bioscience Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Zivo Bioscience Inc?

Currently, no hedge funds are holding shares in ZIVO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Zivo Bioscience Inc

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

ZIVO Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","11":"$11","17":"$17","23":"$23","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,5,11,17,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2023","6":"Jan<br/>2024","9":"Nov<br/>2024","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.95,11.03076923076923,10.11153846153846,9.192307692307692,8.273076923076923,7.3538461538461535,6.434615384615384,5.515384615384615,4.596153846153846,3.6769230769230763,2.7576923076923077,1.838461538461539,0.9192307692307686,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.95,11.03076923076923,10.11153846153846,9.192307692307692,8.273076923076923,7.3538461538461535,6.434615384615384,5.515384615384615,4.596153846153846,3.6769230769230763,2.7576923076923077,1.838461538461539,0.9192307692307686,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.95,11.03076923076923,10.11153846153846,9.192307692307692,8.273076923076923,7.3538461538461535,6.434615384615384,5.515384615384615,4.596153846153846,3.6769230769230763,2.7576923076923077,1.838461538461539,0.9192307692307686,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.216,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.42,"date":1667260800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.76,"date":1675209600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.68,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.34,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.498,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.96,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19.8,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >